ER Congressi

SESSION I

Key note lecture: pathogenesis of PNH

L. Luzzatto (Firenze)

Somatic mutation in nonmalignant disease

N.S. Young (Bethesda, USA)

Complement biology in PNH

R.P. Taylor (Charlottesville, USA)

PNH and aplastic anemia

G. Socié (Paris, France)

SESSION II

PNH: a scientific journey from bench to the patient

P. Hillmen (Leeds, UK)

C5 inhibition as disease modifying treatment, present and future

J. Panse (Aachen, Germany)

Unmet needs in PNH

C. Frieri (Avellino)

Adding new dimensions to proximal inhibition: transforming paroxysmal nocturnal haemoglobinuria (PNH) management. Broadening horizons with proximal inhibition in PNH

A. Kulasekararaj (London, UK)

PATIENT'S VIEW

Patient reported outcomes in PNH

E.N. Oliva (Reggio Calabria)

PNH global alliance

M. Piggin (London, UK)

The Max Foundation

A. Annamalay (Seattle, USA)

SESSION III

The biology of clonal hematopoiesis in PNH

J.P. Maciejewski (Cleveland, USA)

Classical treatment of PNH: when complement inibitors were (or are) not available

H. Schrezenmeier (Hessen, Germany)

SESSION IV

The biology of complement inhibition in PNH

C. Schmidt (Ulm, Germany)

Mechanisms of MAC inhibition by CD59

D.A. Bubeck (London, UK)

SESSION V: CONTROVERSIES IN PNH - BTH, definition and clinical significance

BTH, definition and clinical significance

H. Schrezenmeier (Hessen, Germany)

SESSION V: CONTROVERSIES IN PNH - Is the allogeneic stem cell transplantation still an option for PNH therapy?

Is the allogeneic stem cell transplantation still an option for PNH therapy?

C. Frieri (Avellino)

Is the allogeneic stem cell transplantation still an option for PNH therapy?

A. Kulasekararaj (London, UK)

SESSION V: Hypoplasia in PNH: to treat or not to treat?

Hypoplasia in PNH: to treat or not to treat?

A. Bacigalupo (Roma) - H. Schrezenmeier (Hessen, Germany)

SESSION V: Thrombosis: prevention and therapy in anticomplement era

Thrombosis: prevention and therapy in anticomplement era

A.P. Iori (Roma)